Skip to main content

Advertisement

SpringerLink
Log in

A Novel Self-Assembly Nanocrystal as Lymph Node-Targeting Delivery System: Higher Activity of Lymph Node Targeting and Longer Efficacy Against Lymphatic Metastasis

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

Mitoxantrone (MTO) is used to treat certain types of cancer, mostly metastatic cancer. While the drug has poor aqueous solubility and high side effects. Self-assembly nanocrystal is a novel lymphatic targeting delivery system. In our study, MTO self-assembly nanocrystal (MTO NC) was successfully prepared to improve lymphatic targeting ability and reduce its toxicity. MTO NCs had small size, stable potential, and uniform distribution. The average particle size of MTO NCs was less than 100 nm with the 0.218 PDI and − 6.6 mV the Zeta potential value. TEM images showed that MTO NCs had a sphere-like morphology with smooth surface and uniform distribution; Atomic force microscopy (AFM) images gave a 3D surface of MTO NCs. Polarizing microscope micrograph (PLM) of MTO NCs in lymph nodes demonstrated the crystal structure of MTO NCs when it was exposed to physiological condition. Transmission electron microscopy showed the presence of MTO NCs in mice lymph nodes. Pharmacokinetic parameters of MTO strongly demonstrated that MTO NCs could target the lymph nodes after subcutaneous injection. Moreover, tissue distribution results indicated that MTO NCs were mainly absorbed by the lymphatics and reduced system toxicity. Finally, a lymphatic metastasis mice model was established to precede the pharmacodynamics of MTO NCs, and using MTO liposomes as a reference preparation, the inhibitory effect of MTO NCs on lymphatic metastasis was markedly higher. Briefly, MTO NCs, as a novel self-assembled lymphatic targeting system, can accumulate in the metastatic lymph nodes and lead anticancer drug to kill cancer cells and control lymphatic metastasis with extremely low systemic toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106:1624–33.

    Article  Google Scholar 

  2. Kawada K, Taketo MM. Significance and mechanism of lymph node metastasis in cancer progression. Cancer Res. 2011;71:1214–8.

    Article  CAS  Google Scholar 

  3. van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for research and treatment of cancer 10801 trial. J Natl Cancer Inst. 2000;92:1143–50.

    Article  Google Scholar 

  4. Thomas SN, Rutkowski JM, Pasquier M, Kuan EL, Alitalo K, Randolph GJ, et al. Impaired humoral immunity and tolerance in K14-VEGFR-3-Ig mice that lack dermal lymphatic drainage. J Immunol. 2012;189(5):2181–90.

    Article  CAS  Google Scholar 

  5. Lund AW, Duraes FV, Hirosue S, Raghavan VR, Nembrini C, Thomas SN, et al. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep. 2012;1(3):191–9.

    Article  CAS  Google Scholar 

  6. Betticher DC, Hsu Schmitz S-F, Tötsch M, Hansen E, Joss C, von Briel C, et al. Mediastinal lymph node clearance After docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non–small-cell lung cancer: a multicenter phase II trial. J Clin Oncol. 2003;21:1752–9.

    Article  CAS  Google Scholar 

  7. Alvarado R, Yi M, Le-Petross H, Gilcrease M, Mittendorf EA, Bedrosian I, et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 2012;19:3177–84.

    Article  Google Scholar 

  8. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583–92.

    Article  CAS  Google Scholar 

  9. Kerjaschki D. The lymphatic vasculature revisited. J Clin Invest. 2014;124:874–7.

    Article  CAS  Google Scholar 

  10. Mohrman DE, Heller LJ, Physiology CV. 6th. New York: McGraw-Hill Companies; 2006.

    Google Scholar 

  11. Cueni LN, Detmar M. New insights into the molecular control of the lymphatic vascular system and its role in disease. J Invest Dermatol. 2006;126:2167–77.

    Article  CAS  Google Scholar 

  12. Pawar VK, Singh Y, Meher JG. Engineered nanocrystal technology: In-vivo fate, targeting and applications in drug delivery. J Control Release. 2014;183:51–66.

    Article  CAS  Google Scholar 

  13. Zhang XY, Lu WY. Recent advances in lymphatic targeted drug delivery system for tumor metastasis. Cancer Biol Med. 2014;11(4):247–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Lehn JM. Toward self-organization and complex matter. Science. 2002;295:2400–3.

    Article  CAS  Google Scholar 

  15. Zhang S. Fabrication of novel biomaterials through molecular self-assembly. Nat Biotechnol. 2003;21:1171–8.

    Article  CAS  Google Scholar 

  16. Mendes AC, Baran ET, Reis RL, Azevedo HS. Self-assembly in nature: using the principles of nature to create complex nanobiomaterials. Wires Nanomed Nanobiol. 2013;5:582–612.

    Article  CAS  Google Scholar 

  17. Sosnik A. Drug self-assembly: a phenomenon at the nanometer scale with major impact in the structure–biological properties relationship and the treatment of disease. Prog Mater Sci. 2016;82:39–82.

    Article  CAS  Google Scholar 

  18. Lock LL, La Comb M, Schwarz K, Cheetham AG, Lin Y, Zhang P. Self-assembly of natural and synthetic drug amphiphiles into discrete supramolecular nanostructures. Faraday Discuss. 2013;166:285–301.

    Article  CAS  Google Scholar 

  19. Taboada P, Gutierrez-Pichel M, Mosquera V. Chem Phys. 2004;298:65–74.

    Article  CAS  Google Scholar 

  20. Coltman CA Jr, McDaniel TM, Balcerzak SP. Mitoxantrone hydrochloride (NSC-310739) in lymphoma. Invest New Drug. 1983;1(1):65–70.

    Article  Google Scholar 

  21. Beijnen JH, Bult A, Underberg WJM, Analytical profiles of drug substances. 1988;17:221–258

  22. Supersaxo A, Hein WR, Steffen H. Pharm Res. 1990;7(2):167–9.

    Article  CAS  Google Scholar 

  23. Porter CJ, Charman WN. Adv Drug Deliv Rew. 2001;50(1–2):1.

    CAS  Google Scholar 

  24. Liu J,et al. Bio-self-assembled nanocrystalline injection with lymphatic targeting function and its preparation method. 2017;CN201710486510.8.

  25. Li J, King AV, Stickel SL. Vaccine. 2007;27(4):558–64.

    Article  Google Scholar 

  26. Ugwu S, Zhang A, Parmar M. Preparation, characterization, and stability of liposome-based formulations of mitoxantrone. Drug Dev Ind Pharm. 2005;31(2):223–9.

    Article  CAS  Google Scholar 

  27. Schwendener RA, Fiebig HH, Berger MR, Berger DP. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy*. Cancer Chemother Pharmacol. 1991;27(6):429–39.

    Article  CAS  Google Scholar 

  28. Wang J, Kang WM, Yu JC, Liu YQ, Meng QB, Cao ZJ. Cadherin-17 induces tumorigenesis and lymphatic metastasis in gastric cancer through activation of NFκB signaling pathway. Cancer Biol Ther. 2013;14:262–70.

    Article  CAS  Google Scholar 

  29. Xiong SB, Lu B, Yang H, et al. Study on the tissue distribution and lymph node targeting of mitoxantrone loaded albumin nanoparticles RP-HPLC method for determination of mitoxantrone in rat plasma and different tissues. Chin J Pharm Anal. 2006;26(8):1043–9.

    CAS  Google Scholar 

  30. Rentsch K, Horber D, Schwendener R, Wunderli-Allenspach H, Hänseler E. Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. Br J Cancer. 1997;75(7):986–92.

    Article  CAS  Google Scholar 

  31. Law SL, Jang TF, Chang P, et al. Release characteristics of mitoxantrone-containing liposomes. Int J Pharm. 1994;103(1):81–5.

    Article  CAS  Google Scholar 

  32. Sato DYO, Wal R, De Oliveira CC. Histopathological and immunophenotyping studies on normal and sarcoma 180-bearing mice treated with a complex homeopathic medication. Homeopathy. 2005;94(1):26–32.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We wish to acknowledge the support of Pharmacy Laboratory Centre and Animal Centre of Shenyang Pharmaceutical University.

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China

    Yuling Mao, Tianyu Shi & Shujun Wang

  2. School of Pharmacy, China Pharmaceutical University, Nanjing, China

    Jun Liu

  3. Department of General Surgery, Peking Union Medical College Hospital, Beijing, China

    Ge Chen

Authors
  1. Yuling Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tianyu Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ge Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shujun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shujun Wang.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mao, Y., Liu, J., Shi, T. et al. A Novel Self-Assembly Nanocrystal as Lymph Node-Targeting Delivery System: Higher Activity of Lymph Node Targeting and Longer Efficacy Against Lymphatic Metastasis. AAPS PharmSciTech 20, 292 (2019). https://doi.org/10.1208/s12249-019-1447-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12249-019-1447-3

KEY WORDS

Search

Navigation